Antiphospholipid Syndrome: Statement Analysis

Statements a, d, and e are TRUE; statements b and c are FALSE.

Statement-by-Statement Analysis

a) Risk of thrombotic events is higher in patients with positive anti-β2-GPI antibodies or lupus anticoagulant - TRUE

This statement is correct. The most recent 2025 ISTH guidance confirms that anti-β2-glycoprotein I (anti-β2GPI) antibodies and lupus anticoagulant (LA) are the major autoantibodies responsible for thrombotic risk in APS 1. Specifically:

LA positivity and anti-β2GPI antibodies represent the highest-risk serological profile for thrombotic events
Triple positivity (LA + anti-β2GPI + anticardiolipin) confers the greatest thrombotic risk, with LA-positive patients showing an 85% prevalence of additional antibodies 1
IgG variants of anti-β2GPI show stronger association with clinical thrombotic events compared to IgM 1
Multiple studies confirm that LA and anti-β2GPI are more strongly associated with thrombosis than anticardiolipin antibodies alone 2, 3

The evidence consistently demonstrates that these two antibody types are superior markers for identifying patients at risk for thromboembolic complications.

b) Termed secondary when occurring in the context of a malignant neoplasm - FALSE

This statement is incorrect. Secondary APS refers to APS occurring in the context of other autoimmune diseases, particularly systemic lupus erythematosus (SLE), not malignancy 4, 3, 5.

Secondary APS is most commonly associated with SLE 5
Primary APS occurs when patients have neither clinical nor laboratory evidence of another definable autoimmune condition 5
The distinction is between primary (isolated) versus secondary (associated with autoimmune disease), not related to malignancy 6

While antiphospholipid antibodies may occasionally be detected in patients with malignancies, this does not define secondary APS according to established classification criteria.

c) Recurrent pregnancy loss in women and exclusively recurrent arterial thromboses - FALSE

This statement is incorrect because APS causes BOTH arterial AND venous thromboses, not exclusively arterial. The 2023 ACR/EULAR classification criteria include six clinical domains, with both venous thromboembolism and arterial thrombosis as separate entities 7.

APS is characterized by venous OR arterial thrombosis, often multiple 4, 5
Venous thromboembolism is actually more common than arterial thrombosis in many APS cohorts 8
The syndrome can affect "any arterial or venous vascular territory" 9
Recurrent pregnancy loss is indeed a major manifestation, but the thrombotic component is not limited to arterial events 6

The word "exclusively" makes this statement definitively false.

d) Concomitant thrombocytopenia in some patients - TRUE

This statement is correct. Thrombocytopenia is a well-recognized feature of APS and is now included in the 2023 ACR/EULAR classification criteria 7.

Thrombocytopenia is one of the six clinical domains in the 2023 classification criteria 7
It is "frequently accompanied by a moderate thrombocytopenia" in APS patients 5
Thrombocytopenia is significantly associated with IgM antiphospholipid antibodies 1
It represents a common clinical feature beyond the classic thrombotic and obstetric manifestations 4

The thrombocytopenia in APS is typically moderate rather than severe, distinguishing it from other thrombocytopenic disorders.

e) Manifests as Budd-Chiari syndrome - TRUE

This statement is correct. APS can manifest as Budd-Chiari syndrome (hepatic vein thrombosis), as APS-related thrombosis can affect any vascular territory.

APS can cause thrombosis in "any arterial or venous vascular territory" 9
The syndrome is characterized by "venous and arterial thromboses, often multiple" that can occur at various anatomical sites 5
Hepatic vein thrombosis (Budd-Chiari syndrome) is a recognized manifestation of the hypercoagulable state in APS
Other unusual sites of thrombosis are well-documented in APS, including renal microangiopathy and various organ systems 4

While not the most common presentation, Budd-Chiari syndrome is an established manifestation of APS's prothrombotic state.

Key Clinical Pitfalls

Common diagnostic errors to avoid:

Do not assume all antiphospholipid antibodies carry equal thrombotic risk - LA and anti-β2GPI are the highest-risk markers 1
Do not confuse secondary APS (autoimmune-associated) with antibodies detected in malignancy - these are distinct entities 5
Do not limit your thrombotic assessment to arterial events only - venous thromboembolism is equally or more common 8, 9
Do not overlook thrombocytopenia - it is now part of formal classification criteria and aids in diagnosis 7
Do not dismiss unusual thrombotic sites - APS can affect any vascular bed, including hepatic veins 9

Have a follow-up question?